Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.46 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27192645 | 1.00 | CASP3 (0.46) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL32669193 | 0.87 | CASP3 (0.52) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL6749693 | 0.81 | MDM4 (0.51) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL30878000 | 0.80 | CASP3 (0.53) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL22144908 | 0.80 | CASP3 (0.53) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL1667845 | 0.80 | CASP3 (0.53) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL14761328 | 0.80 | KMT2A (0.50) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL30186613 | 0.80 | CASP3 (0.53) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL16003177 | 0.80 | CASP3 (0.53) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL14407149 | 0.80 | CASP3 (0.53) | CASP3MDM4TP53KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116945-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024049931-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116945-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | TOP1, TOP2A, TOP2B | CASP3 215/4885MDM4 3321/4885TP53 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.